Week Ending October 31, 2022

FLASH Radiation Therapy Shows Promise in First-in-human Trial
“FLASH radiation treatment – which delivers therapeutic doses of radiation in a fraction of a second – may hold promise as a potential treatment for tough-to-kill tumors, a first-in-human study in a small number of people with bone cancer suggests.”

Adjuvant Nivolumab Drastically Reduces Risk of Recurrence or Death in Patients with Stage IIB or IIC Melanoma
“Patients with completely resected stage IIB or IIC melanoma who received adjuvant nivolumab experienced a 58% reduction in the risk of recurrence or death.”

November Is Lung Cancer Awareness Month – What You Need to Know About Screenings
“Lung cancer is by far the leading cause of cancer death, making up nearly 25 percent of all cancer deaths. More than 130,000 U.S. adults die from lung cancer each year – more than breast, colon and prostate cancer deaths combined.”

Clinical Trial Data on TILs in Non-Small Cell Lung Cancer (NSCLC)
“In the second installment of the series, Ben Creelan, MD, reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.”

How Dangerous Is It for Lung Cancer Patients to Skip Radiation Treatments?
“As doctors work toward developing more personalized cancer care, a new study looks at whether lung cancer patients can miss a few days of radiation treatment and make them up with a higher dose.”

Minorities face longer wait times for vital lung cancer treatment, study finds
“A new study has revealed significant racial disparities in how quickly minorities with the most common form of lung cancer receive potentially lifesaving radiation therapy compared with their white counterparts.”

Looking Forward in EGFR+ and KRAS+ NSCLC
“Andreas Saltos, MD, discusses what he anticipates future research will examine regarding treatment options for EGFR and KRAS-mutated non-small cell lung cancer.”

Circadian rhythm disruptions linked to increased risk of lung cancer, study shows
“Biological clocks in almost every cell in the body regulate your sleep-wake pattern over the course of 24 hours. This pattern is known as your circadian rhythm and is underpinned by a molecular feedback loop — the transcription-translation feedback loop — involving specific genes and their protein products.”

Targeted lung cancer drug shows promise in phase I/II clinical trial
“Early trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain type of non-small cell lung cancer (NSCLC).”

First-Line Toripalimab Plus Chemotherapy in Advanced NSCLC: CHOICE-01
“As reported in the Journal of Clinical Oncology by Wang et al, a Chinese phase III trial (CHOICE-01) has shown prolonged progression-free survival with the addition of the anti–PD-1 monoclonal antibody toripalimab to platinum-based chemotherapy in the first-line treatment of patients with advanced non–small cell lung cancer (NSCLC) without EGFR/ALK alterations.”